Understanding the Treatment Strategies of Intracranial Germ Cell Tumors: Focusing on Radiotherapy.
10.3340/jkns.2015.57.5.315
- Author:
Joo Young KIM
1
;
Jeonghoon PARK
Author Information
1. Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, Korea. jooyoungcasa@ncc.re.kr
- Publication Type:Review
- Keywords:
Intracranial germ cell tumor;
ICGCT;
Radiotherapy;
Proton beam therapy;
Biology
- MeSH:
Biology;
Brain Neoplasms;
Chemoradiotherapy;
Child;
Craniospinal Irradiation;
Drug Therapy;
Germinoma;
Humans;
Neoplasms, Germ Cell and Embryonal*;
Proton Therapy;
Radiotherapy*;
Radiotherapy, Intensity-Modulated;
Recurrence;
Survival Rate;
Treatment Outcome
- From:Journal of Korean Neurosurgical Society
2015;57(5):315-322
- CountryRepublic of Korea
- Language:English
-
Abstract:
Intracranial germ cell tumors (ICGCT) occur in 2-11% of children with brain tumors between 0-19 years of age. For treatment of germinoma, relatively low radiation doses with or without chemotherapy show excellent 10 year survival rate of 80-100%. Past studies showed that neoadjuvant chemotherapy combined with focal radiotherapy resulted in unacceptably high rates of periventricular tumor recurrence. The use of generous radiation volume which covers the whole ventricular space with later boost treatment to primary site is considered as standard treatment of intracranial germinomas. For non-germinomatous germ cell tumors (NGGCT), 10-year overall survival rate is still much inferior than that of intracranial germinoma despite intensive chemotherapy and high-dose radiotherapy. Craniospinal radiotherapy combined with cisplatin-based chemotherapy provides the best treatment outcome for NGGCT; 60-70% of overall survival rate. There is a debate on the surgical role whether surgery can contribute to improved treatment outcome of NGGCT when added to combined chemoradiotherapy. Because higher dose of radiotherapy is required for treatment of NGGCT than for germinoma, it is tested whether whole ventricular irradiation can replace craniospinal irradiation in intermediate risk group of NGGCT to minimize radiation-related late toxicity in the recent studies. To minimize the treatment-related neural deficit and late sequelae while maintaining long-term survival rate of ICGCT patients, optimized administration of chemotherapy and radiotherapy should be selected. Use of technically upgraded radiotherapy modalities such as intensity-modulated radiotherapy or proton beam therapy is expected to bring an improved neurocognitive outcome with longitudinal assessment of the patients.
